Alkem Laboratories Ltd Analyst Rating
based on 21 analysts
45.00%
Buy
30.00%
Hold
25.00%
Sell
Based on 21 analysts offering long term price targets for Alkem Laboratories Ltd. An average target of ₹5775.29
Source: S&P Global Market Intelligence
Alkem Laboratories Ltd Share analysis
Alkem Laboratories Ltd price forecast by 21 analysts
Upside of5.12%
High
₹7225
Target
₹5775.29
Low
₹4330
Alkem Laboratories Ltd target price ₹5775.29, a slight upside of 5.12% compared to current price of ₹5427.5. According to 21 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Alkem Laboratories Ltd revenue growth forecast
Expected growth rate Q1, FY2026:16.36%
Forecast
Actual
Including amortisation and stock based compensations
Alkem Laboratories Ltd EPS growth forecast
EPS estimate Q1, FY2026:39.61%
Forecast
Actual
Source: S&P Global Market Intelligence
Alkem Laboratories Ltd Performance
Day's Low
Day's High
₹5,404.8Day's Price Range₹5,543.2552 Week's Low
52 Week's High
₹4,407.0552-Week Price Range₹6,439.9
| Returns % | |
| 1 Month Return | -1.97 % |
| 3 Month Return | -8.16 % |
| 1 Year Return | + 11.9 % |
| Market Stats | |
| Previous Close | ₹5,494.25 |
| Open | ₹5,535.00 |
| Volume | 1.13L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹65,680.04Cr |
Alkem Laboratories Ltd Key Statistics
| P/E Ratio | 30.95 |
| PEG Ratio | 0.54 |
| Market Cap | ₹65,680.04 Cr |
| P/B Ratio | 5.6 |
| EPS | 151.52 |
| Dividend Yield | 0.81 |
| Sector | Pharmaceuticals |
| ROE | 17.56 |
Alkem Laboratories Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹65,680.04 Cr | 34.85% | 0.56 | ₹1,811 Cr | ₹12,667 Cr | |
| HOLD | ₹25,400.23 Cr | 21.5% | 0.55 | ₹362 Cr | ₹2,226 Cr | |
| HOLD | ₹30,567.64 Cr | 136.37% | 0.67 | ₹168 Cr | ₹5,040 Cr | |
| BUY | ₹10,991.10 Cr | 14.19% | 0.64 | ₹119 Cr | ₹547 Cr | |
| BUY | ₹5,268.71 Cr | 15.57% | 0.54 | ₹69 Cr | ₹571 Cr |
About Alkem Laboratories Ltd
With its headquarters in Mumbai, India, Alkem Laboratories is engaged in the manufacture of a wide range of pharmaceutical products across multiple therapeutic categories, including cardiovascular, central nervous system, gastro-intestinal, anti-infective, diabetology, and nutrition. The company has a strong presence in the Indian market and exports its products to over 50 countries.
Share Price: ₹5427.50 per share as on 20 Dec, 2024 04:01 PM
Market Capitalisation: ₹65,680.04Cr as of today
Revenue: ₹3,414.67Cr as on September 2024 (Q3 24)
Net Profit: ₹701.96Cr as on September 2024 (Q3 24)
Listing date: 23 Dec, 2015
Chairperson Name: Basudeo N Singh
| Organisation | Alkem Laboratories Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Alkem Laboratories Ltd
Alkem Laboratories Invests in Renewable Energy Project - 18 Dec, 2024
Alkem Laboratories, along with its subsidiary Enzene Biosciences, has signed an agreement to acquire a 26% stake in Sunsure Solarpark for Rs 1.95 crore, enhancing its renewable energy portfolio.Promoter Group Member Makes Luxury Purchase Amid Share Sale - 13 Dec, 2024
Seema Singh, part of Alkem Laboratories' promoter group, purchased a luxury apartment for Rs 185 crore after divesting over 3.58 lakh shares worth Rs 177 crore.Alkem Transfers Trade Generics Business to Subsidiary - 10 Dec, 2024
Alkem Laboratories has approved the transfer of its trade generics business to its wholly owned subsidiary, Alkem Wellness, for up to ₹750 crore. The transaction aims to enhance business agility and market penetration, with completion expected by March 31, 2025.Alkem Laboratories Ltd Sees Positive Momentum - 02 Dec, 2024
Alkem Laboratories Ltd shares rose 1.4% to Rs 5721.55, marking a 24.03% increase over the past year. The stock has gained for three consecutive sessions, despite a 1.32% drop in the last month. The Nifty Pharma index is up 1.08% today, while the overall market shows modest gains.BofA Raises Concerns on Alkem Laboratories - 28 Nov, 2024
Bank of America has expressed concerns regarding structural challenges in the domestic pharmaceutical sector, leading to an Underperform rating on Alkem Laboratories due to margin risks and muted growth outlooks.Alkem Laboratories Gains from Stake Sale and MSCI Inclusion - 26 Nov, 2024
Alkem Laboratories saw a 0.82% stake sold by UBS for Rs 541.16 crore. The stock price rose after this deal, and MSCI inclusion is expected to bring $2.5 billion inflows.Alkem Laboratories Joins MSCI Global Standard Index - 24 Nov, 2024
Alkem Laboratories will be included in the MSCI Global Standard Index starting Monday, leading to an expected net FII passive inflow of approximately $2.5 billion into India.
Insights on Alkem Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 3 quarters, 3.02K Cr → 3.54K Cr (in ₹), with an average increase of 7.6% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 8.69% to 9.02% in Sep 2024 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 14.73% to 14.94% in Sep 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 293.56 Cr → 688.64 Cr (in ₹), with an average increase of 33.5% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, ALKEM stock has moved up by 1.1%
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 57.1% return, outperforming this stock by 45.8%
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 135.8% return, outperforming this stock by 72.9%
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 56.38% to 55.66% in Sep 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 16.36% to 16.10% in Sep 2024 quarter
Alkem Laboratories Ltd Financials
Index Inclusions
Alkem Laboratories Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 55.66% | ||
| Foreign Institutions | 9.02% | 3.80 | |
| Mutual Funds | 14.94% | 1.45 | |
| Retail Investors | 16.1% | ||
| Others | 4.27% | 10.99 |
Alkem Laboratories Ltd Key Indicators
Alkem Laboratories Ltd Valuation
Alkem Laboratories Ltd in the last 5 years
Lowest (20.07x)
March 24, 2021
Today (30.95x)
December 19, 2024
Industry (56.23x)
December 19, 2024
Highest (44.21x)
August 9, 2023
Alkem Laboratories Ltd Earnings and Dividends
Alkem Laboratories Ltd Earnings Results
Alkem Laboratories Ltd’s net profit jumped 10.98% since last year same period to ₹688.64Cr in the Q2 2024-2025. On a quarterly growth basis, Alkem Laboratories Ltd has generated 26.32% jump in its net profits since last 3-months.
Read More about Earnings ResultsAlkem Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Alkem Laboratories Ltd has declared dividend of ₹5 - translating a dividend yield of 0.74%.
Read More about Dividends
Alkem Laboratories Ltd Technicals Summary
Bearish
Neutral
Bullish
Alkem Laboratories Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Alkem Laboratories Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Alkem Laboratories Ltd shares.
Alkem Laboratories Ltd (ALKEM) share price today is ₹5427.5
Alkem Laboratories Ltd is listed on NSE
Alkem Laboratories Ltd is listed on BSE
- Today’s highest price of Alkem Laboratories Ltd is ₹5543.25.
- Today’s lowest price of Alkem Laboratories Ltd is ₹5404.8.
PE Ratio of Alkem Laboratories Ltd is 30.95
PE ratio = Alkem Laboratories Ltd Market price per share / Alkem Laboratories Ltd Earnings per share
Today’s traded volume of Alkem Laboratories Ltd(ALKEM) is 1.13L.
Today’s market capitalisation of Alkem Laboratories Ltd(ALKEM) is ₹65680.04Cr.
| Alkem Laboratories Ltd(ALKEM | Price |
|---|---|
52 Week High | ₹6439.9 |
52 Week Low | ₹4407.05 |
Alkem Laboratories Ltd(ALKEM) share price is ₹5427.5. It is down -15.72% from its 52 Week High price of ₹6439.9
Alkem Laboratories Ltd(ALKEM) share price is ₹5427.5. It is up 23.15% from its 52 Week Low price of ₹4407.05
| Alkem Laboratories Ltd(ALKEM | Returns |
|---|---|
1 Day Returns | -66.75% |
1 Month Returns | -1.97% |
3 Month Returns | -8.16% |
1 Year Returns | 11.9% |